Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

ANGPT2-L

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

ANGPT2-L	Pancreatic Ductal Adenocarcinoma	ANGPT2-L	Pancreatic Ductal Adenocarcinoma	nivolumab Sensitive: C3 – Early Trials ESMO-IO 2022 - 1 week (New C3) nivolumab Sensitive : C3 ESMO-IO 2022 - 1wk	nivolumab Sensitive: C3 – Early Trials ESMO-IO 2022 - 1 week nivolumab Sensitive : C3 ESMO-IO 2022 - 1 week - (New C3)
ANGPT2-L	Pancreatic Ductal Adenocarcinoma	ANGPT2-L	Pancreatic Ductal Adenocarcinoma	nivolumab + ipilimumab Sensitive: C3 – Early Trials ESMO-IO 2022 - 1 week (New C3) nivolumab + ipilimumab Sensitive : C3 ESMO-IO 2022 - 1wk	nivolumab + ipilimumab Sensitive: C3 – Early Trials ESMO-IO 2022 - 1 week nivolumab + ipilimumab Sensitive : C3 ESMO-IO 2022 - 1 week - (New C3)
ANGPT2-L	Hepatocellular Cancer	ANGPT2-L	Hepatocellular Cancer	lenvatinib Sensitive: C3 – Early Trials lenvatinib Sensitive : C3	lenvatinib Sensitive: C3 – Early Trials lenvatinib Sensitive : C3
ANGPT2-L	Hepatocellular Cancer	ANGPT2-L	Hepatocellular Cancer	pembrolizumab + lenvatinib Sensitive: C3 – Early Trials pembrolizumab + lenvatinib Sensitive : C3	pembrolizumab + lenvatinib Sensitive: C3 – Early Trials pembrolizumab + lenvatinib Sensitive : C3